Steve De Vos
Mechelen-bovelingen, VLG 2800, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Inhibition of Salt-Inducible Kinases 2 and 3 reduces inflammatory signature in Psoriasis.
Journal: The Journal of investigative dermatology
Published: January 14, 2026
Structure-Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 Inhibitor.
Journal: Journal of medicinal chemistry
Published: July 25, 2025
Structure activity relationship exploration of imidazo[1,2-a]pyridine series to reverse isoform selectivity and identify potent SIK1 selective inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: July 03, 2025
Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes.
Journal: JCI insight
Published: July 03, 2025
When assessing representative images of fine-needle aspirate cytological smears of canine mast cell tumours, interobserver agreement is influenced by educational attainment.
Journal: The Journal of small animal practice
Published: June 06, 2024
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Journal: Journal of medicinal chemistry
Published: May 28, 2024
Design of a potent and selective dual JAK1/TYK2 inhibitor.
Journal: Bioorganic & medicinal chemistry
Published: May 07, 2024
Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.
Journal: Journal of medicinal chemistry
Published: March 29, 2024
Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312.
Journal: Journal of medicinal chemistry
Published: December 26, 2023
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
Journal: Science translational medicine
Published: February 15, 2023
Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.
Journal: Journal of medicinal chemistry
Published: September 09, 2020
The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis.
Journal: Journal of clinical medicine
Published: March 08, 2020
Last Updated: 09/26/2026